Trade Gilead ^GILD

Nurix Extends Gilead Oncology Research Collaboration For Two Years

Zacks Research Lowers Earnings Estimates for Gilead Sciences

Gilead (NASDAQ: GILD) CEO sells 15,000 shares under a preset plan - Zolmax

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

31,384 Gilead Sciences, Inc. $GILD Shares Sold by CX Institutional

Biotech Stocks To Watch Now - October 2nd - Daily Political

Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock

Biotech Stocks To Watch Now - October 2nd - Zolmax

Gilead Sciences (NASDAQ:GILD) Stock: Insider Daniel Patrick O'day Sells 15,000 Shares - Daily Political

Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD

HIV prevention drug hailed as breakthrough, but who gets access?

Gilead Sciences (NASDAQ:GILD) Stock Rating Cut to "Hold" at Zacks Research

Zacks Research Downgrades Gilead Sciences (NASDAQ:GILD) to Hold - Stock Observer

GILD: HIV Growth Still Leads, Oncology And Immunology Now Carry More Weight

Vascular Dementia Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2034 - DelveInsight | Pfizer, Gilead Sciences, ViiV Healthcare | ABNewswire

Best Medical Stocks To Watch Today - September 29th - Markets Daily

Best Pharmaceutical Stocks To Follow Now - September 26th - Daily Political

Can Lenacapavir Power Gilead Sciences (GILD)'s Next Growth Phase?

Promising Pharmaceutical Stocks To Research - September 28th - Zolmax

Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?

Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?

Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend?

A human single-cell atlas identifies OLR1 + scar-associated macrophages as a potential therapeutic target for chronic liver disease

Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?

Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?

Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?

Gilead's HIV Concentration or Pfizer's Patent Cliff: Which Risk is Easier to Own?

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts

Reviewing Gilead Sciences (NASDAQ:GILD) & Protalix BioTherapeutics (NYSE:PLX) - Stock Observer

Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc.

FY2026 EPS Estimate for Gilead Sciences Boosted by Analyst - Daily Political

Biotech Stocks To Follow Now - September 23rd - Stock Observer

Medical Stocks To Watch Today - September 22nd - Stock Observer

FY2027 EPS Forecast for Gilead Sciences Boosted by Analyst - Daily Political

Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know

State Street Corp Raises Position in Gilead Sciences, Inc. $GILD

Gilead Sciences FY2026 EPS Increased by Erste Group Bank

Biotech Stocks To Consider - September 19th - Zolmax

BMY vs GILD: Which Biotech Stock Looks More Attractive Now?

Drugmakers move closer to launch landmark HIV drug as CDSCO eases approval process

Biotech Stocks To Watch Now - September 21st - Daily Political

Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig

GILD: HIV Prevention Promise Faces A Harder Test, Growth Still Looks Thin

Erste Group Bank Estimates Gilead Sciences FY2027 Earnings

Why Morgan Stanley likes Gilead's HIV prevention play

Gilead Sciences (NASDAQ:GILD) Rating Increased to Buy at Wall Street Zen

Gilead Sciences (NASDAQ:GILD) Upgraded to Buy at Wall Street Zen

Insider Selling: Gilead Sciences (NASDAQ:GILD) CFO Sells $435,870.00 in Stock - Daily Political

Gilead Strengthens HIV Growth Platform with Expanded Latin America Access

Top Medical Stocks To Watch Today - September 18th - Daily Political

Nykredit A S Invests $140.59 Million in Gilead Sciences, Inc. $GILD

Top Medical Stocks To Keep An Eye On - September 17th - Stock Observer

Dr Reddy's inks licensing deal with Gilead for once-yearly HIV lenacapavir

Biotech Stocks To Keep An Eye On - September 17th - Stock Observer

Dr Reddy's Labs Secures License for Gilead's Revolutionary Once-Yearly HIV Prevention Drug, ETPharma

Dr. Reddy's expands Gilead pact for HIV prevention drug

Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells $432,660.00 in Stock

Johanna Mercier Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - Stock Observer

Gilead Partners with PAHO to Expand Access to HIV Prevention Drug in Latin America and Caribbean, ETPharma

Medical Stocks To Consider - September 15th - Zolmax

Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances - Stock Observer

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences Target of Unusually High Options Trading (NASDAQ:GILD) - Daily Political

Gilead Sciences, Inc. (GILD) To Go Ex-Dividend on September 15th

Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

The Manufacturers Life Insurance Company Sells 148,344 Shares of Gilead Sciences, Inc. $GILD

Bullseye Investment Management LLC Takes Position in Gilead Sciences, Inc. $GILD

Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales

16,506 Shares in Gilead Sciences, Inc. $GILD Bought by Bullseye Investment Management LLC - Stock Observer

Best Medical Stocks To Research - September 11th - Daily Political

Baird Financial Group Inc. Grows Holdings in Gilead Sciences, Inc. $GILD

RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)

Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth

Tidal Investments LLC Raises Position in Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Shares Acquired by National Pension Service

112,886 Shares in Gilead Sciences, Inc. $GILD Purchased by Engineers Gate Manager LP - Zolmax

Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode - Stock Observer

Triple Negative Breast Cancer Market to Reach Significant Growth by 2036, Driven by Advancements in Immunotherapy, Targeted Therapies, and Next-generation Treatment Approaches | DelveInsight | ABNewswire

Promising Medical Stocks To Research - September 9th - Markets Daily

Sofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive Partner | Morningstar

NewEdge Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD

Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights

Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead | Morningstar

Arizona State Retirement System Raises Stock Holdings in Gilead Sciences, Inc. $GILD - Daily Political

Gilead Sciences, Inc. $GILD Shares Purchased by Groupe la Francaise

California State Teachers Retirement System Has $30.47 Billion Stake in Gilead Sciences, Inc. $GILD

Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market?

Promising Biotech Stocks To Consider - September 7th - Zolmax

GBP/USD Forecast: Can Sterling Hold 1.32 as Fed Rate-Hike Bets Rise?

AUD to USD Forecast 2026–2030: Can the Aussie Reclaim 0.71 After the RBA’s Fourth Rate Hike?

USD/CAD Forecast 2026–2030: Can Fed–BoC Rate Divergence Push the Pair Above 1.42?

PCE+GDP: A Double Data Shock Could Move Markets

Is SpaceX a Good Stock to Buy in 2026?

Best Gold Stock to Buy Now: 6 Gold Stocks to Watch in 2026

Advanced CFD Trading Tools Review: Which Tools Can Improve Your Trading Decisions?

Gold Price Trend 2024-2026: From $2,000 to Record Highs, What Comes Next?

Upcoming IPOs 2026: The Biggest Companies to Watch and Major Listings So Far

x402 Ecosystem Competition Analysis: Launchpads, Facilitators, and Providers

Micron Q4 Earnings Preview: AI Memory Demand Sets High Bar for MU Stock

NFP Preview: US Jobs Report to Test Fed Rate-Hike Expectations

Brent Eases as Gulf Exports Recover and US Offers Reserve Oil

Gold Price Today: Gold Steadies Near $4,180 After Sharp Selloff

Meta Stock Rises 3.24% as Muse Enterprise AI Push Gains Momentum

AMD Stock Falls 3.6% as Oil and Treasury Yields Rise; $8.2 Billion World Labs Deal Announced After Close

US Stocks Fall as Dow Drops 347 Points; Chip Shares Slide Despite Nvidia Buyback

Nvidia Stock Rises as Record $150 Billion Buyback Defies Chip Selloff